PET MRI for Carcinoma, Hepatocellular

1
Effectiveness
1
Safety
Toronto General Hospital, Toronto, Canada
Carcinoma, Hepatocellular+3 More
PET MRI - Device
Eligibility
18+
All Sexes
Eligible conditions
Carcinoma, Hepatocellular

Study Summary

This study is evaluating whether a PET scan can predict the biological behavior of HCC.

See full description

Eligible Conditions

  • Carcinoma, Hepatocellular
  • Carcinoma
  • Relapse
  • Recurrence
  • Hepatocellular Carcinoma

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether PET MRI will improve 1 primary outcome and 2 secondary outcomes in patients with Carcinoma, Hepatocellular. Measurement will happen over the course of 3 years.

3 years
18F-FDG PET/MRI are related to presence of circulating tumor DNA in plasma
18F-FDG PET/MRI can predict HCC's poor tumoral differentiation
18F-FDG PET/MRI results can identify aggressive HCC behavior and recurrence post transplant

Trial Safety

Safety Estimate

1 of 3

Trial Design

2 Treatment Groups

Control
PET MRI Arm

This trial requires 20 total participants across 2 different treatment groups

This trial involves 2 different treatments. PET MRI is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

PET MRI Arm
Device
Patient enrolled in the study will have a PET MRI exam scheduled before transplant
ControlNo treatment in the control group

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly 3 years for reporting.

Closest Location

Toronto General Hospital - Toronto, Canada

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 6 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Histological or radiological diagnosis of HCC (AASLD guidelines)
Listed for LT at UHN
Enrolled in ctDNA study (15-5925)
Able to undergo PET and MRI examination
Willingness and ability of patient to provide signed voluntary informed consent.
Adults (age ≥ 18-years old)

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is pet mri safe for people?

Add answer

There was no obvious harm in the use of PET in cirrhotic patients with hepatocellular carcinoma and no sign of serious toxicity. However, there was not a chance to assess any improvement, so the potential value remained unclear. Therefore, we cannot confirm its use in cirrhotic patients with HCC in our practice.

Unverified Answer

What are the signs of carcinoma, hepatocellular?

Add answer

Most patients with cirrhosis have no signs of carcinoma. The signs and symptoms of carcinoma are not the same in patients with cirrhosis or in patients with viral hepatitis.

Unverified Answer

What are common treatments for carcinoma, hepatocellular?

Add answer

A variety of anticancer agents including 5-Fu are used to treat HCC. In addition, Hepatitis B virus (HBV) infection-related HCC is treated with IFN-α, ALT, HBV-related drugs (such as lamivudine, adefovir dipivoxil, or entecavir) and radiotherapy, especially in cases without HCC, even if there is no concurrent HBV hepatitis.

Unverified Answer

How many people get carcinoma, hepatocellular a year in the United States?

Add answer

The majority of persons with a prior diagnosis of CH, not ascertained to be an HCC at the diagnosis of CH, are likely to get another HCC.

Unverified Answer

What causes carcinoma, hepatocellular?

Add answer

Multiple genetic and environmental factors must interact in a complex manner to develop hepatocarcinoma. The role of hepatitis B virus, hepatitis C virus, HBV, and alcohol consumption is most well established.

Unverified Answer

Can carcinoma, hepatocellular be cured?

Add answer

The high overall survival rates following surgery in patients with hepatocellular carcinoma are surprising. Although these results are based on a relatively low number of patients, we believe that the low operative mortality and the long-term survival time warrant consideration for hepatocellular carcinoma in the adjuvant treatment protocol.

Unverified Answer

What is carcinoma, hepatocellular?

Add answer

Cancer, hepatocellular, is a malignant tumor of the liver that originates from epithelia. Its primary cause is liver cirrhosis. Treatment is multimodal and is based on the type and stage of the tumor and associated liver disease.\n

Unverified Answer

Have there been other clinical trials involving pet mri?

Add answer

One-off use of PET-MRI does not appear to be of benefit for detecting, staging and planning therapeutic intervention in patients with HCC. The clinical application of PET-MRI is currently limited by the relatively poor resolution and insufficient signal integrity associated with this form of imaging, and this restricts its application to selected patients who are sufficiently motivated to undertake the procedure. As such, PET-MRI cannot be regarded as a viable alternative to imaging with PET alone.

Unverified Answer

Has pet mri proven to be more effective than a placebo?

Add answer

This first randomized controlled study demonstrated that pet mri therapy had minimal effect compared to placebo group. Therefore, in case of negative results, we should stop using pet mri for the treatment of HCC.

Unverified Answer

What is the average age someone gets carcinoma, hepatocellular?

Add answer

Liver cancers (especially HCCs) tend to occur later in life than previously appreciated, mainly due to improvements in imaging and detection technologies, but also partly due to an expanded lifespan.

Unverified Answer

Does pet mri improve quality of life for those with carcinoma, hepatocellular?

Add answer

PETM is an effective technique in improving quality of life in patients with carcinoma, hepatocellular. It should be offered to all inpatients who meet certain criteria for image quality enhancement.

Unverified Answer

What is the latest research for carcinoma, hepatocellular?

Add answer

There are two areas for research in hepatocellular carcinoma: 1. Hepatocellular carcinoma in cirrhosis and 2. HCC in non-cirrhotic livers. In particular, there are a number of molecules and proteins that are promising targets for research for hepatocellular carcinoma. Such molecules are the E2F- family, p53, Bcl-2, cyclin D1, and retinoblastoma protein in association with signal transduction networks.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Carcinoma, Hepatocellular by sharing your contact details with the study coordinator.